Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No difference in death rates among patients exposed to common rheumatoid arthritis drugs

08.08.2012
Study compares overall mortality in TNF inhibitors: Humira, Enbrel, and Remicade

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden—the first to compare mortality rates among patients treated with individual TNF inhibitors—is now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

RA is a chronic, autoimmune disease characterized by inflammation in the joints that causes pain, tenderness and swelling. The World Health Organization estimates that RA affects up to one percent of individuals worldwide, with more than one million Americans diagnosed with the disease according to the ACR. Rheumatologists recommend early intervention with biologic disease modifying anti-rheumatic drugs (DMARDs) such as TNF inhibitors to slow disease progression, improve function, and prevent disability.

In Sweden nearly 15% of RA patients are prescribed TNF inhibitors. The present study examined the mortality rates in RA patients exposed to adalimumab, etanercept, or infliximab. "Understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing RA," said lead author Dr. Julia Fridman Simard with the Clinical Epidemiology Unit at Karolinska Institute in Stockholm, Sweden.

Researchers linked data from the Swedish Biologics Register (ARTIS), a comprehensive database of patients initiating first-ever biologic therapy for rheumatic diseases, and information from national Swedish registers that included data such as all-cause mortality, demographics, and RA characteristics. Between 2003 and 2008, 1,609 patients with RA initiated treatment with adalimumab, 2,686 with etanercept, and 2,027 with infliximab as their first ever biologic DMARD.

There were more than 19,000 person-years of follow-up during the five-year study period during which time 211 patients died (3.3%). "While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with RA," concludes Dr. Simard.

This study is published in Arthritis & Rheumatism. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com.

Full Citation: "Mortality in Patients with Rheumatoid Arthritis Treated with TNF Inhibitors: Drug-Specific Comparisons in the Swedish Biologics Register." Julia F Simard, Martin Neovius, Johan Askling for the ARTIS study group. Arthritis & Rheumatism; Published Online: August 8, 2012 (DOI: 10.1002/art.34582).

Author Contact: To arrange an interview with Dr. Simard, please contact Presstjänsten (Press office) with Karolinska Institutet at +46 (0)8-524 860 77.

About the Journal:

Arthritis & Rheumatism is an official journal of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP), a division of the College, and covers all aspects of inflammatory disease. The American College of Rheumatology (www.rheumatology.org) is the professional organization who share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art .

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.

Our core businesses publish scientific, technical, medical, and scholarly journals, encyclopedias, books, and online products and services; professional/trade books, subscription products, training materials, and online applications and Web sites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

Media Advisory

2012 ACR/ARHP Annual Meeting Press Registration Now Open.

What: Press registration is now open to journalists planning to attend the 2012 ACR/ARHP Annual Meeting

Where: Walter E. Washington Convention Center; Washington, D.C.

When: November 10 - 14, 2012

Policies: Please make sure to review our press guidelines www.annualmeeting.org/Press as they may impact your ability to receive press credentials

Registration: To register for a press pass, please visit www.annualmeeting.org/Press

Key dates:

Press registration closes: Monday, October 29, 2012

Press conference schedule announced: September

On-site Newsroom opens: Saturday, November 10, 2012

Opening Lecture/Embargo lifts: 4:30 PM Eastern Time on Saturday, November 10, 2012

Contact: Suzanne Forte, sforte@rheumatology.org, 404-633-3777.

Headquartered in Atlanta, Ga., the American College of Rheumatology is an international professional medical society that represents more than 8,500 rheumatologists and rheumatology health professionals. Rheumatologists are internists or pediatricians who are qualified by training and experience in the diagnosis and treatment of arthritis and other diseases of the joints, muscles and bones. Over 50 million Americans - including nearly 300,000 children - suffer from the painful, disabling and sometimes fatal effects of arthritis and rheumatic diseases. The ACR's mission is to advance rheumatology. Learn more by visiting www.rheumatology.org. or follow ACR on Twitter at www.twitter.com/acrheum.

Dawn Peters | EurekAlert!
Further information:
http://www.wiley.com

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>